| | |
| Clinical data | |
|---|---|
| Trade names | Tenuate, Tepanil, Nobesine, others |
| Other names | Diethylpropion, Diethylcathinone |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a682037 |
| License data | |
| Pregnancy category |
|
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Elimination half-life | 4–6 hours (metabolites) [7] |
| Excretion | Urine (>75%) [7] |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.001.836 |
| Chemical and physical data | |
| Formula | C13H19NO |
| Molar mass | 205.301 g·mol−1 |
| 3D model (JSmol) | |
| Chirality | Racemic mixture |
| |
| |
| | |
Amfepramone, also known as diethylpropion, is a stimulant drug of the phenethylamine, amphetamine, and cathinone classes that is used as an appetite suppressant. [8] [9] It is used in the short-term management of obesity, along with dietary and lifestyle changes. [8] Amfepramone has a similar chemical structure to the antidepressant and smoking cessation aid bupropion (previously called amfebutamone), which has also been developed as a weight-loss medicine when in a combination product with naltrexone. [10]
Amfepramone itself lacks any affinity for the monoamine transporters and instead functions as a prodrug to ethcathinone. [11] Ethcathinone (and therefore amfepramone as well) is a very weak dopaminergic and serotonergic, and is approximately 10× and 20× stronger on norepinephrine in comparison, respectively. [11]
Amfepramone can be synthesized from propiophenone by bromination, followed by reaction with diethylamine. [12] [13]
Another medically utilized name is diethylpropion (British Approved Name (BAN) and Australian Approved Name (AAN)). Chemical names include: α-methyl-β-keto-N,N-diethylphenethylamine, N,N-diethyl-β-ketoamphetamine and N,N-diethylcathinone. Brand names include: Anorex, Linea, Nobesine, Prefamone, Regenon, Tepanil and Tenuate.
Amfepramone is classified as a Schedule IV controlled substance in the United States. In the UK amfepramone is a class C drug [14] and as a medicine, it is a Schedule 3 Controlled Drug which requires safe custody.
As of June 2022, the safety committee of the European Medicines Agency (EMA) recommends the withdrawal of marketing authorizations for amfepramone. [15] [6]
The authors of several studies of amfepramone claim that the substance has a relatively low potential for causing addiction in users. [16] [17] [4] [18]